DRL receives US FDA approval for treatment of acute migraine episodes

ZEMBRACESymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan

US Food and Drug Administration (US FDA) has approved Dr Reddy’s Laboratories (DRL’s) ZEMBRACESymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens.

ZEMBRACESymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously.

ZEMBRACESymTouch is the first branded product in our neurology portfolio. ZEMBRACESymtouch will be marketed in the US by Promius Pharma, a wholly-owned specialty company of DRL.